Browsing Tag
Type 2 Diabetes
42 posts
Glenmark Pharmaceuticals (NSE: GLENMARK) launches GLIPIQ semaglutide in India at Rs 325 a week as generic GLP-1 era starts
Glenmark Pharmaceuticals launches GLIPIQ semaglutide in India from Rs 325 a week. Analysis of pricing, competition, and what it means for GLP-1 access. Read more.
March 21, 2026
Lifeward (Nasdaq: LFWD) bets on oral insulin platform to escape medical device treadmill
Lifeward (LFWD) posts full-year 2025 revenue of $22M, down 14%, as shareholders approve the Oramed POD platform deal. Here is what it means for LFWD investors. Read more.
March 18, 2026
Novo Nordisk’s amycretin delivers 14.5% weight loss in type 2 diabetes trial: A dual-agonist breakthrough?
Novo Nordisk’s amycretin delivers up to 14.5% weight loss in type 2 diabetes trial. Explore the trial data and what’s next in the GLP‑1 drug race.
December 1, 2025
Innovent Biologics hits 20% weight loss in Phase 3: Will mazdutide become China’s Ozempic?
Mazdutide 9 mg achieves 20.08% weight loss in pivotal Chinese Phase 3 study. Learn what this means for Innovent Biologics’ NDA plans and obesity treatment.
November 20, 2025
Lilly’s orforglipron proves oral GLP-1 power with impressive Phase 3 diabetes data
Find out how Eli Lilly’s oral GLP-1 drug orforglipron excelled in Phase 3 trials and could become a foundational therapy for type 2 diabetes.
October 15, 2025
Biomea Fusion reports positive 52-week phase II results showing non-chronic icovamenib treatment benefits in type 2 diabetes
Find out how Biomea Fusion’s 52-week phase II results point to a regenerative, non-chronic path for type 2 diabetes treatment.
October 6, 2025
Metabolics Pharma’s ENT-03 shows promising Phase 1a data in obese and type 2 diabetic patients at ADA 2025
Metabolics Pharma’s ENT-03 shows Phase 1a success in obese and diabetic subjects, with plans for Phase 1b in late 2025. Learn about its brain-based mechanism.
June 26, 2025
Semaglutide shows significant vascular benefits in PAD patients with type 2 diabetes, STRIDE trial confirms
Semaglutide improves walking capacity and reduces disease progression in PAD patients with type 2 diabetes, STRIDE trial results reveal at ADA 2025.
June 22, 2025
Gan & Lee Pharmaceuticals reveals competitive Phase 2 results for bofanglutide and GZR4 at ADA 2025 sessions
Gan & Lee Pharmaceuticals presented strong Phase 2 results for bofanglutide and GZR4 in type 2 diabetes, advancing its long-acting diabetes pipeline.
June 21, 2025
Neodyne Biosciences and Gan & Lee Pharmaceuticals reveal major clinical advances in diabetes care at ADA 2025
Neodyne Biosciences and Gan & Lee Pharmaceuticals presented major ADA 2025 clinical results showing new treatment paths for lipohypertrophy and type 2 diabetes.
June 21, 2025